See more : China Oceanwide Holdings Limited (0715.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Cardiovascular Systems, Inc. (CSII) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cardiovascular Systems, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- TES Touch Embedded Solutions (Xiamen) Co., Ltd. (003019.SZ) Income Statement Analysis – Financial Results
- Seanergy Maritime Holdings Corp. (SHIPZ) Income Statement Analysis – Financial Results
- Magna Mining Inc. (NICU.V) Income Statement Analysis – Financial Results
- Etablissements Maurel & Prom S.A. (MAU.PA) Income Statement Analysis – Financial Results
- Jilin Chemical Fibre Stock Co.,Ltd (000420.SZ) Income Statement Analysis – Financial Results
Cardiovascular Systems, Inc. (CSII)
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 236.22M | 258.97M | 236.55M | 248.02M | 217.04M | 204.91M | 178.18M | 181.54M | 136.61M | 103.90M | 82.49M | 78.78M | 64.83M | 56.46M | 58.57M | 15.99M | 441.00K | 834.00K | 726.00K | 0.00 |
| Cost of Revenue | 63.44M | 61.13M | 48.76M | 47.68M | 39.48M | 39.44M | 35.42M | 39.52M | 31.04M | 24.38M | 19.22M | 16.28M | 15.00M | 16.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 172.78M | 197.84M | 187.79M | 200.34M | 177.56M | 165.47M | 142.76M | 142.02M | 105.57M | 79.52M | 63.27M | 62.50M | 49.83M | 40.27M | 58.57M | 15.99M | 441.00K | 834.00K | 726.00K | 0.00 |
| Gross Profit Ratio | 73.14% | 76.39% | 79.39% | 80.78% | 81.81% | 80.75% | 80.12% | 78.23% | 77.28% | 76.53% | 76.71% | 79.34% | 76.86% | 71.32% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 36.72M | 41.06M | 43.36M | 33.46M | 26.76M | 22.91M | 25.93M | 30.98M | 21.07M | 15.22M | 11.37M | 8.94M | 10.28M | 14.68M | 43.31M | 38.30M | 29.18M | 16.28M | 0.00 | 2.52M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 167.70M | 148.57M | 144.10M | 162.54M | 143.68M | 117.99M | 86.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 170.53M | 167.50M | 169.97M | 167.70M | 148.57M | 144.10M | 162.54M | 143.68M | 117.99M | 86.72M | 66.37M | 62.37M | 62.45M | 59.82M | 13.02M | 12.19M | 5.33M | 2.99M | 0.00 | 1.28M |
| Other Expenses | 1.34M | 1.22M | 1.23M | 760.00K | -390.00K | -164.00K | 53.00K | -162.00K | -706.00K | -671.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 208.59M | 209.78M | 214.56M | 201.16M | 175.33M | 167.01M | 188.48M | 174.66M | 139.06M | 101.93M | 77.74M | 71.31M | 72.73M | 74.50M | 56.33M | 50.48M | 34.51M | 19.28M | 0.00 | 3.79M |
| Cost & Expenses | 272.03M | 270.91M | 263.32M | 248.84M | 214.81M | 206.45M | 223.90M | 214.18M | 170.10M | 126.32M | 96.96M | 87.59M | 87.73M | 90.69M | 56.33M | 50.48M | 34.51M | 19.28M | 0.00 | 3.79M |
| Interest Income | 817.00K | 499.00K | 1.74M | 2.44M | 1.33M | 383.00K | 0.00 | 0.00 | 0.00 | -1.62M | 5.00K | 12.00K | 402.00K | 3.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.63M | 1.74M | 1.97M | 1.68M | 1.72M | 500.00K | 0.00 | 23.00K | 1.03M | 1.35M | 2.32M | 1.42M | 1.44M | 2.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.34M | 1.22M | 1.23M | 3.45M | 3.93M | 4.14M | 3.92M | 2.32M | 1.37M | 973.00K | 872.00K | 716.00K | 600.00K | 470.00K | 2.25M | 683.00K | 1.29M | 1.30M | 0.00 | 0.00 |
| EBITDA | -34.46M | -10.72M | -25.54M | -825.00K | 2.23M | -1.54M | -35.35M | -32.64M | -33.49M | -22.42M | -14.47M | -8.81M | -22.33M | -35.07M | -963.00K | -39.07M | -32.78M | -16.68M | 726.00K | -3.79M |
| EBITDA Ratio | -14.59% | -4.14% | -10.80% | -0.33% | 1.03% | -0.75% | -19.84% | -17.98% | -24.51% | -21.58% | -17.54% | -11.18% | -34.44% | -62.12% | -1.64% | -244.37% | -7,431.97% | -1,999.76% | 100.00% | 0.00% |
| Operating Income | -35.81M | -11.93M | -26.77M | -825.00K | -1.70M | -1.54M | -56.08M | -32.64M | -33.49M | -22.42M | -14.47M | -8.81M | -22.90M | -34.23M | 2.24M | -34.49M | -34.07M | -18.44M | 726.00K | -3.79M |
| Operating Income Ratio | -15.16% | -4.61% | -11.32% | -0.33% | -0.78% | -0.75% | -31.47% | -17.98% | -24.51% | -21.58% | -17.54% | -11.18% | -35.32% | -60.63% | 3.82% | -215.75% | -7,725.17% | -2,211.27% | 100.00% | 0.00% |
| Total Other Income/Expenses | -817.00K | -1.24M | -233.00K | 760.00K | 3.54M | -164.00K | 53.00K | -185.00K | -1.80M | -1.62M | -2.32M | 0.00 | 28.00K | 1.31M | 5.45M | 5.26M | 399.00K | -797.00K | 0.00 | 0.00 |
| Income Before Tax | -36.62M | -13.17M | -27.01M | -65.00K | 1.84M | -1.71M | -56.02M | -32.82M | -35.29M | -24.04M | -15.44M | 0.00 | -22.87M | -32.93M | 7.69M | -29.24M | -33.67M | -19.24M | 0.00 | 0.00 |
| Income Before Tax Ratio | -15.50% | -5.09% | -11.42% | -0.03% | 0.85% | -0.83% | -31.44% | -18.08% | -25.83% | -23.14% | -18.72% | 0.00% | -35.28% | -58.31% | 13.13% | -182.86% | -7,634.69% | -2,306.83% | 0.00% | 0.00% |
| Income Tax Expense | 310.00K | 252.00K | 231.00K | 190.00K | 132.00K | 86.00K | 6.39M | -2.30M | -333.00K | 344.00K | 479.00K | 1.60M | 1.01M | -25.12M | -5.45M | -5.25M | 0.00 | 797.00K | 13.95M | 3.76M |
| Net Income | -36.93M | -13.42M | -27.24M | -255.00K | 1.71M | -1.79M | -56.02M | -32.82M | -35.29M | -24.04M | -16.79M | -11.13M | -23.90M | -9.11M | 7.69M | -29.25M | -33.67M | -19.24M | -13.95M | -3.76M |
| Net Income Ratio | -15.63% | -5.18% | -11.51% | -0.10% | 0.79% | -0.87% | -31.44% | -18.08% | -25.83% | -23.14% | -20.35% | -14.12% | -36.87% | -16.14% | 13.13% | -182.94% | -7,634.69% | -2,306.83% | -1,921.49% | 0.00% |
| EPS | -0.94 | -0.35 | -0.79 | -0.01 | 0.05 | -0.06 | -1.72 | -1.04 | -1.25 | -1.11 | -0.93 | -0.70 | -1.62 | -1.13 | 2.90 | -21.03 | -323.00 | -257.79 | -208.20 | -53.01 |
| EPS Diluted | -0.94 | -0.35 | -0.79 | -0.01 | 0.05 | -0.06 | -1.72 | -1.04 | -1.25 | -1.11 | -0.93 | -0.70 | -1.62 | -1.13 | 2.80 | -21.03 | -323.00 | -257.79 | -208.20 | -53.01 |
| Weighted Avg Shares Out | 39.23M | 38.83M | 34.28M | 33.54M | 33.15M | 32.37M | 32.54M | 31.55M | 28.30M | 21.69M | 18.04M | 15.92M | 14.75M | 8.07M | 2.67M | 1.39M | 104.24K | 74.63K | 67.00K | 70.97K |
| Weighted Avg Shares Out (Dil) | 39.23M | 38.83M | 34.28M | 33.54M | 33.61M | 32.37M | 32.54M | 31.55M | 28.30M | 21.69M | 18.04M | 15.92M | 14.75M | 8.07M | 2.77M | 1.39M | 104.24K | 74.63K | 67.00K | 70.97K |
Cytek Biosciences Set to Join S&P SmallCap 600
NEW YORK , April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1. S&P 500 and 100 constituent Abbott...
Cardiovascular Systems (CSII) Finishes ECLIPSE Trial Enrollment
Cardiovascular Systems' (CSII) ECLIPSE clinical trial data is likely to help physicians form an optimal treatment plan for patients with severely calcified coronary arteries.
Cardiovascular Systems, Inc. Completes Enrollment of ECLIPSE Clinical Trial
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the company completed the enrollment of its 2,000 patient ECLIPSE...
Cardiovascular Systems, Inc. Completes Enrollment of ECLIPSE Clinical Trial
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC.
CARDIOVASCULAR SYSTEMS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cardiovascular Systems, Inc. - CSII
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cardiovascular Systems, Inc. (“CSI”) (NasdaqGS: CSII) to Abbott Laboratories (NYSE: ABT)....
CARDIOVASCULAR SYSTEMS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cardiovascular Systems, Inc. - CSII
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cardiovascular Systems, Inc. (“CSI”) (NasdaqGS: CSII) to Abbott Laboratories (NYSE: ABT)....
Cardiovascular Systems (CSII) Ails From Soft Volume, Macro Woes
Tough competition and consistent net loss continue to pose threats to Cardiovascular Systems (CSII).
Abbott Acquires Cardiovascular Systems: Key Takeaways For Investors
Abbott Laboratories expands its cardiovascular pipeline with the relatively small acquisition of Cardiovascular Systems, Inc. Cardiovascular Systems investors get a way out of a cash-burning stock at a decent price. The timing of the deal is opportunistic for Abbott.
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Cardiovascular Systems, Inc. - CSII
NEW YORK , Feb. 13, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class...
CARDIOVASCULAR SYSTEMS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cardiovascular Systems, Inc. - CSII
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cardiovascular Systems, Inc. (“CSI”) (NasdaqGS: CSII) to Abbott Laboratories (NYSE: ABT)....
Source: https://incomestatements.info
Category: Stock Reports